Aspira Biohealth LLP Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Aspira Biohealth LLP Pharmaceutical Export Portfolio Dataset — 3 Products, $25.4K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Aspira Biohealth LLP — Pharmaceutical Exporter Profile (2026) | 3 Products, $25.4K Trade | TransData Nexus

Aspira Biohealth LLP

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $25.4K Total Trade · DGFT Verified

Aspira Biohealth LLP is an Indian pharmaceutical exporter with a total trade value of $25.4K across 3 products in 2 therapeutic categories. Based on 30 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Topotecan ($10.0K), Proguanil ($8.0K), Cabazitaxel ($7.5K).

Aspira Biohealth LLP — Export Portfolio & Destination Treemap

Aspira Biohealth LLP pharmaceutical export portfolio — 3 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Aspira Biohealth LLP? — Company Overview & Market Position

Aspira Biohealth LLP is a pharmaceutical exporter based in Salem, Tamil Nadu, India. Established on December 23, 2021, the company operates as a limited liability partnership (LLP) under the Corporate Identification Number (CIN) AAZ-9895. The registered office is located at Shop No SF1, V&V Complex, 237, Chairman Thammanan Road, Arisipalayam, Peramanur, Salem, Tamil Nadu, 636009. The LLP has a total obligation of contribution amounting to ₹3,000,000. As of the latest available data, the company has four designated partners: Annambari Mohamed Shafi Mohamed Nihal, Mahmoud Ahmed Ibrahim Abdalrahman, Valid Mohamad, and Koolachelathi Shaik Mohamed Ansari Shaik Mohamed Shaheer. The company's primary business activity is wholesale trade and commission trade, excluding motor vehicles and motorcycles. Financial details such as revenue and employee count are not publicly disclosed.

What Does Aspira Biohealth LLP Export? — Product Portfolio Analysis

Top Products by Export Value

1Topotecan$10.0K 2Proguanil

Product Portfolio — Top 3 by Export Value

Aspira Biohealth LLP exports 3 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Topotecan	Advanced Oncology	$10.0K	5	0.3%	6
2	Proguanil	Antimalarial & Antiparasitic	$8.0K	11	0.0%	10
3	Cabazitaxel	Advanced Oncology	$7.5K	14	0.1%	11

Aspira Biohealth LLP exports 3 pharmaceutical products across 2 therapeutic categories with a total export value of $25.4K. The top category is Advanced Oncology (68.5% of portfolio), followed by Antimalarial & Antiparasitic (31.5%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Aspira Biohealth LLP — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Specific information regarding Aspira Biohealth LLP's manufacturing facilities, including locations, capacities, and specializations, is not publicly available. The company's export data indicates a focus on finished pharmaceutical formulations, suggesting that manufacturing may be outsourced to third-party contract manufacturers. However, without explicit confirmation, this remains speculative.

3Key Leadership

The leadership team of Aspira Biohealth LLP comprises four designated partners:

Annambari Mohamed Shafi Mohamed Nihal: Appointed on December 23, 2021.
Mahmoud Ahmed Ibrahim Abdalrahman: Appointed on May 11, 2022.
Valid Mohamad: Appointed on May 11, 2022.
Koolachelathi Shaik Mohamed Ansari Shaik Mohamed Shaheer: Appointed on December 23, 2021.

Detailed professional backgrounds and roles within the company are not publicly disclosed.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Aspira Biohealth LLP Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Aspira Biohealth LLP's export data indicates shipments to various international markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's total export value is $25,000 USD, with 30 shipments across three products in two therapeutic categories. The top three products exported are Topotecan ($10,000), Proguanil ($8,000), and Cabazitaxel ($7,000). However, the company does not hold market leader positions in these categories, and its portfolio is highly concentrated, with the top five products accounting for 100% of exports. Specific regulatory filings, approvals, and market access statuses in these regions are not publicly available.

2Emerging Markets

Aspira Biohealth LLP's export data does not provide specific information regarding its presence in emerging markets such as Africa, Latin America, and Southeast Asia. The company's focus appears to be on advanced oncology and antimalarial & antiparasitic products, which may limit its reach in certain emerging markets. Without explicit data, it is challenging to assess the company's penetration in these regions or its alignment with WHO prequalification standards.

3Geographic Strategy

Aspira Biohealth LLP — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding Aspira Biohealth LLP's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's export data does not provide insights into its compliance with FDA regulations or its standing in the U.S. market. Without explicit data, it is challenging to assess the company's FDA status and its ability to meet U.S. regulatory requirements.

2WHO & EU GMP

Aspira Biohealth LLP's export data does not provide information regarding its compliance with World Health Organization (WHO) prequalification or European Union Good Manufacturing Practice (EU GMP) certifications. The company's focus on advanced oncology and antimalarial & antiparasitic products suggests a potential alignment with WHO prequalification standards; however, without explicit confirmation, this remains speculative. Similarly, the absence of data on EU GMP certification limits the assessment of the company's adherence to EU manufacturing standards.

3CDSCO & Indian Regulatory

Aspira Biohealth LLP — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Aspira Biohealth LLP operates in the pharmaceutical export sector, focusing on finished pharmaceutical formulations in the advanced oncology and antimalarial & antiparasitic therapeutic categories. The company's top three products—Topotecan, Proguanil, and Cabazitaxel—are specialized medications with established competitors in the global market. The company's export data indicates a total export value of $25,000 USD, with 30 shipments across three products. This suggests a relatively small market presence compared to larger pharmaceutical exporters. The lack of market leader positions and the high concentration risk in its product portfolio may limit the company's competitiveness in the global market.

2Key Differentiators

Aspira Biohealth LLP's focus on advanced oncology and antimalarial & antiparasitic products positions it in niche therapeutic areas with specific market needs. The company's export data indicates a concentration on a limited number of products, which may allow for specialized expertise and streamlined operations. However, the absence of market leader positions and the high concentration risk in its product portfolio may limit the company's ability to leverage these differentiators for competitive advantage.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Aspira Biohealth LLP as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Aspira Biohealth LLP's export data indicates a total export value of $25,000 USD, with 30 shipments across three products in two therapeutic categories. The company's portfolio is highly concentrated, with the top five products accounting for 100% of exports. This suggests a reliance on a limited number of products and markets, which may impact the company's supply chain stability and growth prospects. The absence of detailed information regarding manufacturing facilities, regulatory compliance, and market presence limits the assessment of the company's overall track record, export volume consistency, and reliability.

2Certifications to Verify

Importers considering partnerships with Aspira Biohealth LLP should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm that the company's products are approved by the U.S. Food and Drug Administration (FDA). This can be verified through the FDA's official website or by contacting the company directly.

WHO-GMP Certification: Ensure that the manufacturing facilities comply with World Health Organization Good Manufacturing Practice (WHO-GMP) standards. Verification can be done by reviewing the company's certifications or contacting the World Health Organization.

Frequently Asked Questions — Aspira Biohealth LLP

How many pharmaceutical products does Aspira Biohealth LLP export from India?

Aspira Biohealth LLP exports 3 pharmaceutical products across 2 therapeutic categories. The top exports are Topotecan ($10.0K), Proguanil ($8.0K), Cabazitaxel ($7.5K). Total export value is $25.4K.

What is Aspira Biohealth LLP's total pharmaceutical export value?

Aspira Biohealth LLP's total pharmaceutical export value is $25.4K, based on 30 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Aspira Biohealth LLP cover?

Aspira Biohealth LLP exports across 2 therapeutic categories. The largest are Advanced Oncology (68.5%, 2 products), Antimalarial & Antiparasitic (31.5%, 1 products).

Get Full Aspira Biohealth LLP Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.